AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22902599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg 8-hourly starting the afternoon before surgery until the fifth postoperative day
Number of subjects: 80
Study 22902599 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 80
Study 22902599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin and Placebo
Number of subjects: 80
Study 20812790 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin theta
Number of subjects: 270
Study 20812790 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 270
Study 17939414 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock with IAH
Number of subjects: 46
Study 17939414 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock without IAH
Number of subjects: 46
Study 17939414 — intervention group
Group type: COMPARATOR
Intervention: Control group (postoperative patients) with IAH
Number of subjects: 46
Study 17939414 — intervention group
Group type: COMPARATOR
Intervention: Control group (postoperative patients) without IAH
Number of subjects: 46
Study 16297748 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study 16297748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic and femoral nerve blocks with 40 mL of 0.375% bupivacaine
Number of subjects: 50
Study 12239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin (subcutaneous, 150 U/kg thrice weekly for a minimum of 4 weeks)
Number of subjects: 0
Study 12239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin (weekly, 40,000 U/wk)
Number of subjects: 0
Study 12239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin (dose escalation if no response)
Number of subjects: 0
Study 12239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin (continuation beyond 6-8 weeks)
Number of subjects: 0
Study 12239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin (titration once Hgb reaches 12 g/dL)
Number of subjects: 0
Study 12239138 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin for patients with anemia associated with low-risk myelodysplasia not receiving chemotherapy
Number of subjects: 0
Study 12239138 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for anemic patients with hematologic malignancies
Number of subjects: 0
Study 9705040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet LF (low fat)
Number of subjects: 45
Study 9705040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet HP (high PUFA)
Number of subjects: 45
Study 9705040 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet HM (high MUFA)
Number of subjects: 45
Study 8557206 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive support program (psychosocial intervention including individual and family counseling, ad hoc counseling, support group participation)
Number of subjects: 0
Study 8557206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 30908627 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy therapist interventions (relational reframes and focus on primary adaptive emotions)
Number of subjects: 30
Study 30908627 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy therapist interventions (interpretations, reassurances, and focus on rejecting anger toward parents)
Number of subjects: 30
Study 30908627 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy therapist interventions (general encouragement of affect and focus on unmet attachment/identity needs)
Number of subjects: 30
Study 27586686 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diary
Number of subjects: 241
Study 27586686 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly diary
Number of subjects: 241
Study 27586686 — intervention group
Group type: COMPARATOR
Intervention: Automated feedback about risk behaviors
Number of subjects: 241
Study 27586686 — intervention group
Group type: COMPARATOR
Intervention: Risk behavior engagement
Number of subjects: 241
Study 27586686 — intervention group
Group type: COMPARATOR
Intervention: Substance use
Number of subjects: 241
Study 26919180 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized adult oxygenator without integrated arterial filter (IAF)
Number of subjects: 68
Study 26919180 — intervention group
Group type: EXPERIMENTAL
Intervention: Full adult oxygenator without integrated arterial filter (IAF)
Number of subjects: 68
Study 26919180 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized adult oxygenator with integrated arterial filter (IAF)
Number of subjects: 68
Study 26919180 — intervention group
Group type: EXPERIMENTAL
Intervention: Full adult oxygenator with integrated arterial filter (IAF)
Number of subjects: 68
Study 26919180 — intervention group
Group type: COMPARATOR
Intervention: Optimized adult oxygenator without IAF
Number of subjects: 68
Study 26919180 — intervention group
Group type: COMPARATOR
Intervention: Full adult oxygenator without IAF
Number of subjects: 68
Study 26919180 — intervention group
Group type: COMPARATOR
Intervention: Optimized adult oxygenator with IAF
Number of subjects: 68
Study 26919180 — intervention group
Group type: COMPARATOR
Intervention: Full adult oxygenator with IAF
Number of subjects: 68
Study 25640050 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 213
Study 25640050 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 213
Study 24095239 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection technique with traction
Number of subjects: 70
Study 24095239 — intervention group
Group type: COMPARATOR
Intervention: Injection technique without traction
Number of subjects: 70
Study 21970555 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 40
Study 21970555 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine
Number of subjects: 40
Study 18315590 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (partial replacement of normal diet with elemental diet for 3 weeks)
Number of subjects: 50
Study 18315590 — intervention group
Group type: COMPARATOR
Intervention: No intervention (normal diet)
Number of subjects: 50
Study 16441715 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sensor rate-responsive pacing with XL or MV sensors
Number of subjects: 105
Study 16441715 — intervention group
Group type: COMPARATOR
Intervention: Dual-sensor rate-responsive pacing
Number of subjects: 105
Study 14627933 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic wellness program (six half-day workshops over 3 months)
Number of subjects: 43
Study 14627933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 10868823 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendar blister pack (CBP)
Number of subjects: 68
Study 10868823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 9491842 — intervention group
Group type: EXPERIMENTAL
Intervention: High vancomycin trough serum levels (> 15 microg/mL)
Number of subjects: 198
Study 9491842 — intervention group
Group type: COMPARATOR
Intervention: Low vancomycin trough serum levels (< 15 microg/mL)
Number of subjects: 198
Study 9491842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin therapy
Number of subjects: 198
Study 9491842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin failures
Number of subjects: 198
Study 8236133 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance plethysmography (IPG) in symptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: COMPARATOR
Intervention: Impedance plethysmography (IPG) in asymptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal DVT in symptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: COMPARATOR
Intervention: Proximal DVT in asymptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Marder score in symptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: COMPARATOR
Intervention: Mean Marder score in asymptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive DVT in symptomatic patients
Number of subjects: 363
Study 8236133 — intervention group
Group type: COMPARATOR
Intervention: Occlusive DVT in asymptomatic patients
Number of subjects: 363
Study 2951802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 400 micrograms
Number of subjects: 12
Study 2951802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms
Number of subjects: 12
Study 2951802 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms plus ipratropium bromide 80 micrograms (Duovent)
Number of subjects: 12
Study 2951802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30317420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite as a haemostatic agent
Number of subjects: 30
Study 30317420 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 30
Study 28574153 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index (≥65) with high proportion of carbohydrate (58% kcal)
Number of subjects: 159
Study 28574153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI≤45) with low proportion of carbohydrate (40% kcal)
Number of subjects: 159
Study 28574153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index with high proportion of carbohydrate
Number of subjects: 159
Study 28574153 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index with low proportion of carbohydrate
Number of subjects: 159
Study 28574153 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing both glycaemic index and proportion of carbohydrates
Number of subjects: 159
Study 25770420 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 66
Study 25770420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24054874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (1.0×10(8) CFU, twice daily)
Number of subjects: 40
Study 24054874 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule (twice daily)
Number of subjects: 40
Study 21401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference co‐located
Number of subjects: 81
Study 21401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Webcast co‐located
Number of subjects: 81
Study 21401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference dispersed
Number of subjects: 81
Study 21401942 — intervention group
Group type: EXPERIMENTAL
Intervention: Webcast dispersed
Number of subjects: 81
Study 18507525 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free injection device (NFID)
Number of subjects: 349
Study 18507525 — intervention group
Group type: COMPARATOR
Intervention: Needle/syringe (NS) followed by NFID
Number of subjects: 349
Study 16609107 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted anesthesia (Er:YAG unit, fluence 3.5 J/cm2, pulse width 600 microseconds, spot diameter 6 mm) with lidocaine 4% cream
Number of subjects: 61
Study 16609107 — intervention group
Group type: COMPARATOR
Intervention: Sham laser with lidocaine 4% cream
Number of subjects: 61
Study 14563743 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and fluticasone
Number of subjects: 1490
Study 14563743 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol and fluticasone
Number of subjects: 1490
Study 10826853 — intervention group
Group type: EXPERIMENTAL
Intervention: tPA (0.25 mg/kg/day in 0.9% saline) for 3 days
Number of subjects: 32
Study 10826853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32
Study 8844349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% Hyaluronic Acid (HA)
Number of subjects: 11
Study 8844349 — intervention group
Group type: COMPARATOR
Intervention: 100% Glycerin (Control)
Number of subjects: 11
Study 1321186 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg twice daily
Number of subjects: 40
Study 1321186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6721970 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (mean 0.24 MAC‐h) with 50% nitrous oxide in oxygen
Number of subjects: 28
Study 6721970 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (mean 0.23 MAC‐h) with 50% nitrous oxide in oxygen
Number of subjects: 28
Study 6721970 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 28
Study 6721970 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 28
Study 6721970 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane or Halothane
Number of subjects: 28
Study 29969907 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram for the treatment of agitation
Number of subjects: 0
Study 25675290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefuroxime axetil 500 mg dose, twice daily for 3 days
Number of subjects: 67
Study 25675290 — intervention group
Group type: COMPARATOR
Intervention: Parenteral cefuroxime axetil 750 mg IV dose, single dose before placement
Number of subjects: 67
Study 24680330 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic application of dexamethasone (DEX) 10 mg×3 d followed by 5 mg×4 d
Number of subjects: 438
Study 24680330 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical injection of methylprednisolone sodium succinate 40 mg every three days
Number of subjects: 438
Study 24680330 — intervention group
Group type: COMPARATOR
Intervention: Local corticosteroids injection in low‐middle frequencies
Number of subjects: 438
Study 23770470 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized growth standard (IS)
Number of subjects: 1588
Study 23770470 — intervention group
Group type: COMPARATOR
Intervention: Population standard (PS)
Number of subjects: 1588
Study 21039759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine (CBM)
Number of subjects: 16
Study 21039759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18165444 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine 0.5 g/kg/d during the first 24 hours of resuscitation and 10 days thereafter
Number of subjects: 20
Study 18165444 — intervention group
Group type: COMPARATOR
Intervention: Control group received isonitrogenous whey powder plus immune‐enhancing diet
Number of subjects: 20
Study 16553675 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 43
Study 16553675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 15242433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 20 micrograms/kg
Number of subjects: 80
Study 15242433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 11408005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels
Number of subjects: 360
Study 11408005 — intervention group
Group type: EXPERIMENTAL
Intervention: apo(a) isoform size <= 22 KIV
Number of subjects: 360
Study 11408005 — intervention group
Group type: EXPERIMENTAL
Intervention: TTTTA repeats >= 10
Number of subjects: 360
Study 11408005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) levels with low apo(a) weight
Number of subjects: 360
Study 11408005 — intervention group
Group type: EXPERIMENTAL
Intervention: (TTTTA)(n) polymorphism
Number of subjects: 360
Study 9430085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty-acid modified, cholesterol-reduced animal fat (FAMCRAF)
Number of subjects: 29
Study 9430085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-reduced animal fat (CRAF)
Number of subjects: 29
Study 9430085 — intervention group
Group type: COMPARATOR
Intervention: Unaltered animal fat (AF)
Number of subjects: 29
Study 7962302 — intervention group
Group type: EXPERIMENTAL
Intervention: L-692,429 (0.2 mg/kg)
Number of subjects: 16
Study 7962302 — intervention group
Group type: EXPERIMENTAL
Intervention: L-692,429 (0.75 mg/kg)
Number of subjects: 16
Study 7962302 — intervention group
Group type: COMPARATOR
Intervention: GHRH (1 microgram/kg)
Number of subjects: 16
Study 7962302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7962302 — intervention group
Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 16
Study 2853764 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol + terbutaline (10 mg/day + 200 mg/day)
Number of subjects: 45
Study 2853764 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (200 mg/day)
Number of subjects: 45
Study 2853764 — intervention group
Group type: COMPARATOR
Intervention: terbutaline (10 mg/day)
Number of subjects: 45
Study 2853764 — intervention group
Group type: COMPARATOR
Intervention: orciprenaline (30 mg/day)
Number of subjects: 45
Study 29806667 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-guided group
Number of subjects: 20
Study 29806667 — intervention group
Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 20
Study 29806667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 26657184 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV glycoprotein B (gB) vaccine with MF59
Number of subjects: 402
Study 26657184 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 402
Study 24169014 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographically guided LV lead positioning
Number of subjects: 151
Study 24169014 — intervention group
Group type: COMPARATOR
Intervention: Remote LV leads
Number of subjects: 151
Study 22258366 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the Australian Cancer Trials web site
Number of subjects: 493
Study 22258366 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 493
Study 20052549 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach preparation
Number of subjects: 12
Study 20052549 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla preparation
Number of subjects: 12
Study 20052549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vegetables
Number of subjects: 12
Study 18780315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (20 mg/m²/day, Days 1-5) and Vinorelbine (6 mg/m² bolus on Day 1 and 6 mg/m²/day continuous infusion on Days 1-5) with concurrent 30-gray fractionated external-beam radiotherapy
Number of subjects: 25
Study 18780315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Vinorelbine with concurrent radiotherapy
Number of subjects: 25
Study 15911360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lamotrigine therapy for 16 weeks
Number of subjects: 547
Study 15911360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy for 12 weeks
Number of subjects: 547
Study 12769163 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg once a day
Number of subjects: 0
Study 12769163 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg once a day
Number of subjects: 0
Study 12769163 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg (1st step)
Number of subjects: 0
Study 12769163 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg (2nd step)
Number of subjects: 0
Study 12769163 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 10654588 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol ester-enriched margarine (8.6 g vegetable oil phytosterols)
Number of subjects: 24
Study 10654588 — intervention group
Group type: COMPARATOR
Intervention: Control margarine (40 g)
Number of subjects: 24
Study 8712422 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV) with size 2 laryngeal mask airway (LMA)
Number of subjects: 46
Study 8712422 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (Control group)
Number of subjects: 46
Study 1650023 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Infusion System (RIS)
Number of subjects: 36
Study 1650023 — intervention group
Group type: COMPARATOR
Intervention: Conventional Fluid Administration (CFA)
Number of subjects: 36
Study 6849742 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 50 mg
Number of subjects: 6
Study 6849742 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 200 mg
Number of subjects: 6
Study 6849742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg
Number of subjects: 6
Study 6849742 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 6
Study 6849742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30621276 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Valine 0.15 kcal/min (total: 3.3 g)
Number of subjects: 12
Study 30621276 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Valine 0.45 kcal/min (total: 9.9 g)
Number of subjects: 12
Study 30621276 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 12
Study 28881472 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab 10 mg/kg IV (single dose)
Number of subjects: 24
Study 28881472 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab 10 mg/kg IV (multiple doses)
Number of subjects: 24
Study 28881472 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab (various doses IV and SC)
Number of subjects: 24
Study 28881472 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab (various doses)
Number of subjects: 24
Study 28881472 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab 20 mg/kg IV
Number of subjects: 24
Study 26847437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum-based markers of speed of clearance of bacilli (time to smear negative status, time to culture negative status on LJ or in MGIT, daily rate of change of log10(TTP) to day 56)
Number of subjects: 0
Study 26847437 — intervention group
Group type: COMPARATOR
Intervention: Reference model adjusted for BMI, history of smoking, HIV status, cavitation, gender and MGIT TTP
Number of subjects: 0
Study 25888092 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pethidine i.v.
Number of subjects: 98